Current Insights and Future Directions in the Treatment of Heart Failure with Preserved Ejection Fraction
Heart failure is a clinical syndrome associated with poor quality of life, substantial healthcare resource utilization, and premature mortality, in large part related to high rates of hospitalizations. The clinical manifestations of heart failure are similar regardless of the ejection fraction. Unli...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2023-12, Vol.25 (1), p.440 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 440 |
| container_title | International journal of molecular sciences |
| container_volume | 25 |
| creator | Chiorescu, Roxana Mihaela Lazar, Roxana-Daiana Ruda, Alexandru Buda, Andreea Paula Chiorescu, Stefan Mocan, Mihaela Blendea, Dan |
| description | Heart failure is a clinical syndrome associated with poor quality of life, substantial healthcare resource utilization, and premature mortality, in large part related to high rates of hospitalizations. The clinical manifestations of heart failure are similar regardless of the ejection fraction. Unlike heart failure with reduced ejection fraction, there are few therapeutic options for treating heart failure with preserved ejection fraction. Molecular therapies that have shown reduced mortality and morbidity in heart failure with reduced ejection have not been proven to be effective for patients with heart failure and preserved ejection fraction. The study of pathophysiological processes involved in the production of heart failure with preserved ejection fraction is the basis for identifying new therapeutic means. In this narrative review, we intend to synthesize the existing therapeutic means, but also those under research (metabolic and microRNA therapy) for the treatment of heart failure with preserved ejection fraction. |
| doi_str_mv | 10.3390/ijms25010440 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10778923</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A779212050</galeid><sourcerecordid>A779212050</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-22d42067106cfcc1bc191bed4168ea58446fdb3d148a03f48fa90606b21fcb3d3</originalsourceid><addsrcrecordid>eNptkk1vFDEMhkcIREvhxhlF4sKhW5yP-TqhatullSqVQzlHmYyzm9VMUpJMUf99M2wpW1TlEMt5_NqO3qL4SOGE8xa-2u0YWQkUhIBXxSEVjC0Aqvr1XnxQvItxC8A4K9u3xQFvGPCKssPCLqcQ0CVy6aJdb1IkyvVkNaUpIDmzAXWy3kViHUkbJDcBVRpn3htygSokslJ2mOHfNm3Ij4ARwx325Hy7KyWroP4E74s3Rg0RPzzeR8XP1fnN8mJxdf39cnl6tdCC12nBWC9YHplCpY3WtNO0pR32glYNqrIRojJ9x3sqGgXciMaoFiqoOkaNznl-VHzb6d5O3Yi9zsMGNcjbYEcV7qVXVj5_cXYj1_5OUqjrpmU8K3x5VAj-14QxydFGjcOgHPopStZSLkRZCprRz_-hWz8Fl_ebKdawzFT_qLUaUFpnfG6sZ1F5WtctowxKyNTJC1Q-PY5We4fG5vyzguNdgQ4-xoDmaUkKcvaG3PdGxj_tf8wT_NcM_AEMFLRJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2912824136</pqid></control><display><type>article</type><title>Current Insights and Future Directions in the Treatment of Heart Failure with Preserved Ejection Fraction</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Chiorescu, Roxana Mihaela ; Lazar, Roxana-Daiana ; Ruda, Alexandru ; Buda, Andreea Paula ; Chiorescu, Stefan ; Mocan, Mihaela ; Blendea, Dan</creator><creatorcontrib>Chiorescu, Roxana Mihaela ; Lazar, Roxana-Daiana ; Ruda, Alexandru ; Buda, Andreea Paula ; Chiorescu, Stefan ; Mocan, Mihaela ; Blendea, Dan</creatorcontrib><description>Heart failure is a clinical syndrome associated with poor quality of life, substantial healthcare resource utilization, and premature mortality, in large part related to high rates of hospitalizations. The clinical manifestations of heart failure are similar regardless of the ejection fraction. Unlike heart failure with reduced ejection fraction, there are few therapeutic options for treating heart failure with preserved ejection fraction. Molecular therapies that have shown reduced mortality and morbidity in heart failure with reduced ejection have not been proven to be effective for patients with heart failure and preserved ejection fraction. The study of pathophysiological processes involved in the production of heart failure with preserved ejection fraction is the basis for identifying new therapeutic means. In this narrative review, we intend to synthesize the existing therapeutic means, but also those under research (metabolic and microRNA therapy) for the treatment of heart failure with preserved ejection fraction.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms25010440</identifier><identifier>PMID: 38203612</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Bioavailability ; Blood vessels ; Body fat ; Cardiomyocytes ; Cardiovascular disease ; Diabetes ; Drug therapy ; Ejection fraction ; Enzymes ; Exercise ; Fitness training programs ; Genotype & phenotype ; Health aspects ; Heart failure ; Heart Failure - therapy ; Humans ; Hypoglycemic agents ; Inflammation ; Ischemia ; Kinases ; Metabolism ; MicroRNAs - genetics ; Mortality ; Musculoskeletal system ; Obesity ; Oxidative stress ; Physical fitness ; Preservation, Biological ; Proteins ; Pulmonary hypertension ; Quality of Life ; Review ; Stroke Volume</subject><ispartof>International journal of molecular sciences, 2023-12, Vol.25 (1), p.440</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c437t-22d42067106cfcc1bc191bed4168ea58446fdb3d148a03f48fa90606b21fcb3d3</cites><orcidid>0000-0002-4137-8582 ; 0000-0001-5906-8024</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10778923/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10778923/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38203612$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chiorescu, Roxana Mihaela</creatorcontrib><creatorcontrib>Lazar, Roxana-Daiana</creatorcontrib><creatorcontrib>Ruda, Alexandru</creatorcontrib><creatorcontrib>Buda, Andreea Paula</creatorcontrib><creatorcontrib>Chiorescu, Stefan</creatorcontrib><creatorcontrib>Mocan, Mihaela</creatorcontrib><creatorcontrib>Blendea, Dan</creatorcontrib><title>Current Insights and Future Directions in the Treatment of Heart Failure with Preserved Ejection Fraction</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Heart failure is a clinical syndrome associated with poor quality of life, substantial healthcare resource utilization, and premature mortality, in large part related to high rates of hospitalizations. The clinical manifestations of heart failure are similar regardless of the ejection fraction. Unlike heart failure with reduced ejection fraction, there are few therapeutic options for treating heart failure with preserved ejection fraction. Molecular therapies that have shown reduced mortality and morbidity in heart failure with reduced ejection have not been proven to be effective for patients with heart failure and preserved ejection fraction. The study of pathophysiological processes involved in the production of heart failure with preserved ejection fraction is the basis for identifying new therapeutic means. In this narrative review, we intend to synthesize the existing therapeutic means, but also those under research (metabolic and microRNA therapy) for the treatment of heart failure with preserved ejection fraction.</description><subject>Bioavailability</subject><subject>Blood vessels</subject><subject>Body fat</subject><subject>Cardiomyocytes</subject><subject>Cardiovascular disease</subject><subject>Diabetes</subject><subject>Drug therapy</subject><subject>Ejection fraction</subject><subject>Enzymes</subject><subject>Exercise</subject><subject>Fitness training programs</subject><subject>Genotype & phenotype</subject><subject>Health aspects</subject><subject>Heart failure</subject><subject>Heart Failure - therapy</subject><subject>Humans</subject><subject>Hypoglycemic agents</subject><subject>Inflammation</subject><subject>Ischemia</subject><subject>Kinases</subject><subject>Metabolism</subject><subject>MicroRNAs - genetics</subject><subject>Mortality</subject><subject>Musculoskeletal system</subject><subject>Obesity</subject><subject>Oxidative stress</subject><subject>Physical fitness</subject><subject>Preservation, Biological</subject><subject>Proteins</subject><subject>Pulmonary hypertension</subject><subject>Quality of Life</subject><subject>Review</subject><subject>Stroke Volume</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkk1vFDEMhkcIREvhxhlF4sKhW5yP-TqhatullSqVQzlHmYyzm9VMUpJMUf99M2wpW1TlEMt5_NqO3qL4SOGE8xa-2u0YWQkUhIBXxSEVjC0Aqvr1XnxQvItxC8A4K9u3xQFvGPCKssPCLqcQ0CVy6aJdb1IkyvVkNaUpIDmzAXWy3kViHUkbJDcBVRpn3htygSokslJ2mOHfNm3Ij4ARwx325Hy7KyWroP4E74s3Rg0RPzzeR8XP1fnN8mJxdf39cnl6tdCC12nBWC9YHplCpY3WtNO0pR32glYNqrIRojJ9x3sqGgXciMaoFiqoOkaNznl-VHzb6d5O3Yi9zsMGNcjbYEcV7qVXVj5_cXYj1_5OUqjrpmU8K3x5VAj-14QxydFGjcOgHPopStZSLkRZCprRz_-hWz8Fl_ebKdawzFT_qLUaUFpnfG6sZ1F5WtctowxKyNTJC1Q-PY5We4fG5vyzguNdgQ4-xoDmaUkKcvaG3PdGxj_tf8wT_NcM_AEMFLRJ</recordid><startdate>20231228</startdate><enddate>20231228</enddate><creator>Chiorescu, Roxana Mihaela</creator><creator>Lazar, Roxana-Daiana</creator><creator>Ruda, Alexandru</creator><creator>Buda, Andreea Paula</creator><creator>Chiorescu, Stefan</creator><creator>Mocan, Mihaela</creator><creator>Blendea, Dan</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4137-8582</orcidid><orcidid>https://orcid.org/0000-0001-5906-8024</orcidid></search><sort><creationdate>20231228</creationdate><title>Current Insights and Future Directions in the Treatment of Heart Failure with Preserved Ejection Fraction</title><author>Chiorescu, Roxana Mihaela ; Lazar, Roxana-Daiana ; Ruda, Alexandru ; Buda, Andreea Paula ; Chiorescu, Stefan ; Mocan, Mihaela ; Blendea, Dan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-22d42067106cfcc1bc191bed4168ea58446fdb3d148a03f48fa90606b21fcb3d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Bioavailability</topic><topic>Blood vessels</topic><topic>Body fat</topic><topic>Cardiomyocytes</topic><topic>Cardiovascular disease</topic><topic>Diabetes</topic><topic>Drug therapy</topic><topic>Ejection fraction</topic><topic>Enzymes</topic><topic>Exercise</topic><topic>Fitness training programs</topic><topic>Genotype & phenotype</topic><topic>Health aspects</topic><topic>Heart failure</topic><topic>Heart Failure - therapy</topic><topic>Humans</topic><topic>Hypoglycemic agents</topic><topic>Inflammation</topic><topic>Ischemia</topic><topic>Kinases</topic><topic>Metabolism</topic><topic>MicroRNAs - genetics</topic><topic>Mortality</topic><topic>Musculoskeletal system</topic><topic>Obesity</topic><topic>Oxidative stress</topic><topic>Physical fitness</topic><topic>Preservation, Biological</topic><topic>Proteins</topic><topic>Pulmonary hypertension</topic><topic>Quality of Life</topic><topic>Review</topic><topic>Stroke Volume</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chiorescu, Roxana Mihaela</creatorcontrib><creatorcontrib>Lazar, Roxana-Daiana</creatorcontrib><creatorcontrib>Ruda, Alexandru</creatorcontrib><creatorcontrib>Buda, Andreea Paula</creatorcontrib><creatorcontrib>Chiorescu, Stefan</creatorcontrib><creatorcontrib>Mocan, Mihaela</creatorcontrib><creatorcontrib>Blendea, Dan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chiorescu, Roxana Mihaela</au><au>Lazar, Roxana-Daiana</au><au>Ruda, Alexandru</au><au>Buda, Andreea Paula</au><au>Chiorescu, Stefan</au><au>Mocan, Mihaela</au><au>Blendea, Dan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current Insights and Future Directions in the Treatment of Heart Failure with Preserved Ejection Fraction</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2023-12-28</date><risdate>2023</risdate><volume>25</volume><issue>1</issue><spage>440</spage><pages>440-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Heart failure is a clinical syndrome associated with poor quality of life, substantial healthcare resource utilization, and premature mortality, in large part related to high rates of hospitalizations. The clinical manifestations of heart failure are similar regardless of the ejection fraction. Unlike heart failure with reduced ejection fraction, there are few therapeutic options for treating heart failure with preserved ejection fraction. Molecular therapies that have shown reduced mortality and morbidity in heart failure with reduced ejection have not been proven to be effective for patients with heart failure and preserved ejection fraction. The study of pathophysiological processes involved in the production of heart failure with preserved ejection fraction is the basis for identifying new therapeutic means. In this narrative review, we intend to synthesize the existing therapeutic means, but also those under research (metabolic and microRNA therapy) for the treatment of heart failure with preserved ejection fraction.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38203612</pmid><doi>10.3390/ijms25010440</doi><orcidid>https://orcid.org/0000-0002-4137-8582</orcidid><orcidid>https://orcid.org/0000-0001-5906-8024</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2023-12, Vol.25 (1), p.440 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10778923 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Bioavailability Blood vessels Body fat Cardiomyocytes Cardiovascular disease Diabetes Drug therapy Ejection fraction Enzymes Exercise Fitness training programs Genotype & phenotype Health aspects Heart failure Heart Failure - therapy Humans Hypoglycemic agents Inflammation Ischemia Kinases Metabolism MicroRNAs - genetics Mortality Musculoskeletal system Obesity Oxidative stress Physical fitness Preservation, Biological Proteins Pulmonary hypertension Quality of Life Review Stroke Volume |
| title | Current Insights and Future Directions in the Treatment of Heart Failure with Preserved Ejection Fraction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T02%3A04%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20Insights%20and%20Future%20Directions%20in%20the%20Treatment%20of%20Heart%20Failure%20with%20Preserved%20Ejection%20Fraction&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Chiorescu,%20Roxana%20Mihaela&rft.date=2023-12-28&rft.volume=25&rft.issue=1&rft.spage=440&rft.pages=440-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms25010440&rft_dat=%3Cgale_pubme%3EA779212050%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2912824136&rft_id=info:pmid/38203612&rft_galeid=A779212050&rfr_iscdi=true |